US-based biotech Noxilizer has appointed David Theil as its new chief financial officer and senior vice president.
Theil has over 25 years of experience in financial, administrative and operational management, specialising in start-up and middle market life sciences companies.
Before joining the biotechnology firm, Theil held various senior management positions at IGEN International, Speciality Pharmaceuticals and Supernus Pharmaceuticals.
He has also served as manager of emerging business markets group for Deloitte & Touche where he worked with clients in biotechnology, communications, healthcare and technology companies.
Lawrence Bruder, Noxilizer’s president and chief executive officer, said: “David brings experience that is critical to Noxilizer at this stage of the company.
“He has worked in growing companies and understands the opportunities and challenges.”